Trial · NCT00700310
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Placebo | -10.69 | Full Range -100.0 to 420.6 | Percent Change | |
| Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Perampanel 2mg | -13.63 | Full Range -100.0 to 346.3 | Percent Change | |
| Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Perampanel 4mg | -23.33 | Full Range -100.0 to 416.0 | Percent Change | |
| Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Perampanel 8 mg | -30.80 | Full Range -100.0 to 390.6 | Percent Change | |
| Responder Rate | Placebo | Responders (Yes) | 17.9 | Percentage of Participants | |
| Responder Rate | Perampanel 2mg | Responders (Yes) | 20.6 | Percentage of Participants | |
| Responder Rate | Perampanel 4mg | Responders (Yes) | 28.5 | Percentage of Participants | |
| Responder Rate | Perampanel 8 mg | Responders (Yes) | 34.9 | Percentage of Participants | |
| Responder Rate | Placebo | Non-Responders (No) | 82.1 | Percentage of Participants | |
| Responder Rate | Perampanel 2mg | Non-Responders (No) | 79.4 | Percentage of Participants | |
| Responder Rate | Perampanel 4mg | Non-Responders (No) | 71.5 | Percentage of Participants | |
| Responder Rate | Perampanel 8 mg | Non-Responders (No) | 65.1 | Percentage of Participants | |
| Percent Change in the 28-day Complex Partial Plus Secondarily Generalized Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Placebo | -17.63 | Full Range -100.0 to 602.9 | Percent Change | |
| Percent Change in the 28-day Complex Partial Plus Secondarily Generalized Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Perampanel 2mg | -20.50 | Full Range -100.0 to 13744.2 | Percent Change | |
| Percent Change in the 28-day Complex Partial Plus Secondarily Generalized Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Perampanel 4mg | -31.18 | Full Range -100.0 to 416.0 | Percent Change | |
| Percent Change in the 28-day Complex Partial Plus Secondarily Generalized Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Perampanel 8 mg | -38.69 | Full Range -100.0 to 583.3 | Percent Change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00700310/results